UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): SEPTEMBER 17, 2007
STEM CELL THERAPY INTERNATIONAL, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
NEVADA 000-51931 88-0374180
(STATE OR OTHER JURISDICTION OF (COMMISSION FILE NUMBER) (I.R.S. EMPLOYER
INCORPORATION OR ORGANIZATION) IDENTIFICATION NO.)
203 N. LOIS AVENUE, 9TH FLOOR, TAMPA, FL 33607
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES - ZIP CODE)
(813) 600-4088
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
NOT APPLICABLE
(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17CFR 240.14d-2(b))
[ ] Pre-commencement communications
1
ITEM 5.02 DEPARTURE OF PRINCIPAL OFFICER AND ELECTION OF PRINCIPAL OFFICER
TAMPA, Fla.-September 17, 2007-Stem Cell Therapy International Inc. (OTC
Bulletin Board: SCII), a leading research and development company in the
regenerative medicine field, announced today the resignation of Daniel J.
Sullivan and the appointment of Andrew J. Norstrud as Chief Financial Officer,
effective September 13, 2007. Mr. Norstrud's time required for this position is
expected to be limited, and although the terms have been agreed upon, the final
contract is still pending and will be filed when completed.
ANDREW J. NORSTRUD - CHIEF FINANCIAL OFFICER
Mr. Norstrud is also the Chief Financial Officer and Senior Vice President of
Jagged Peak Inc., where he has worked since October, 2005 as an integral part of
the executive management team in accelerating their growth, building the
necessary infrastructure and ensuring their compliance with SEC reporting
guidelines. Prior to this, Mr. Norstrud was the Chief Financial Officer of
Segmentz, Inc. from May, 2003 to September, 2005, where he served as Chief
Financial Officer, and played an instrumental role in the company achieving its
strategic goals by pursuing and attaining growth initiatives, building an
exceptional financial team, completing and integrating strategic acquisitions
and implementing the structure required of public companies. The Company grew
its top line revenue from less than $10,000,000 to almost $50,000,000, while he
served as Chief Financial Officer. Previously, Mr. Norstrud has worked for Grant
Thornton LLP (July, 2001 to May, 2003), Norco Accounting and Consulting (May
2002 to present), and Aerosonic and PricewaterhouseCoopers LLP and has extensive
experience with young, rapid growth public companies. Mr. Norstrud earned a
Master of Accounting with a systems emphasis from the University of Florida and
is a Florida licensed Certified Public Accountant.
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
STEM CELL THERAPY INTERNATIONAL, INC.
By: /s/ Andrew J. Norstrud
-----------------------------
Name: Andrew J. Norstrud
Title: Chief Financial Officer
2